IL197212A0 - Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same - Google Patents

Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same

Info

Publication number
IL197212A0
IL197212A0 IL197212A IL19721209A IL197212A0 IL 197212 A0 IL197212 A0 IL 197212A0 IL 197212 A IL197212 A IL 197212A IL 19721209 A IL19721209 A IL 19721209A IL 197212 A0 IL197212 A0 IL 197212A0
Authority
IL
Israel
Prior art keywords
vitamin
administration
compound
methods
therapeutic agent
Prior art date
Application number
IL197212A
Other languages
English (en)
Original Assignee
Cougar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cougar Biotechnology Inc filed Critical Cougar Biotechnology Inc
Publication of IL197212A0 publication Critical patent/IL197212A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL197212A 2006-08-25 2009-02-24 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same IL197212A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
PCT/US2007/018770 WO2008024485A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Publications (1)

Publication Number Publication Date
IL197212A0 true IL197212A0 (en) 2009-12-24

Family

ID=39107444

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197212A IL197212A0 (en) 2006-08-25 2009-02-24 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same

Country Status (9)

Country Link
EP (2) EP2425874A3 (enExample)
JP (1) JP2010501576A (enExample)
KR (1) KR20090060306A (enExample)
CN (1) CN101528309A (enExample)
AU (1) AU2007287099A1 (enExample)
CA (2) CA2661546A1 (enExample)
IL (1) IL197212A0 (enExample)
NO (1) NO20091191L (enExample)
WO (1) WO2008024485A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196308A1 (en) * 2009-01-27 2010-08-05 Jimenez Joaquin J Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
SG176105A1 (en) 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US20120135002A1 (en) * 2009-07-16 2012-05-31 Ivan Cruz Moura Compounds and Methods for the Treatment of Cancer
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
US9029399B2 (en) 2011-04-28 2015-05-12 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
JP2016530219A (ja) 2013-06-05 2016-09-29 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｃｘｃｌ１２活性に関与する疾患を処置するためのビタミンｄ受容体アゴニスト
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4866048A (en) 1985-08-02 1989-09-12 Leo Pharmaceutical Products Ltd. Novel vitamin D analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
DK0633893T3 (da) * 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
WO1999049870A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
ES2300323T3 (es) * 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Also Published As

Publication number Publication date
KR20090060306A (ko) 2009-06-11
NO20091191L (no) 2009-03-23
AU2007287099A1 (en) 2008-02-28
WO2008024485A3 (en) 2009-03-05
EP2425874A3 (en) 2013-05-15
EP2425874A2 (en) 2012-03-07
EP2063963A2 (en) 2009-06-03
WO2008024485A2 (en) 2008-02-28
CA2838089A1 (en) 2008-02-28
JP2010501576A (ja) 2010-01-21
CA2661546A1 (en) 2008-02-28
CN101528309A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
IL185517A0 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
IL178775A0 (en) Pharmaceutical compositions for acute glucocorticoid therapy
GEP20125469B (en) Inhibitors of akt activity
IL186303A (en) 1h - benzamideimzole - 4 carboxyamides converted with quarterly carbon in position 2, the pharmaceutical composition containing it and its use for the preparation of a drug @ for the treatment @ of cancer
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
IL180677A0 (en) Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer
EP2152722A4 (en) COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER
IL202505A (en) 2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses
IL194678A (en) Kinase inhibitors, pharmaceutical preparations containing them and their uses in the preparation of a drug for the treatment of cancer in mammals
SI2063881T1 (sl) Sestavek in postopek za učinkovito in varno dajanje halopiruvata za zdravljenje raka
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
IL197389A0 (en) Prophylactic or therapeutic agent for cancer
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
EP2005954B8 (en) Kit for cancer therapy and pharmaceutical composition for cancer therapy
EP1979487A4 (en) COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
SI1803456T1 (sl) Farmacevtski sestavki, ki obsegajo L-733060, za uporabo pri zdravljenju rakavih tumorjev
GB0625100D0 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
IL226362A0 (en) compounds, and methods for treating cancer